Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer

Journal of Gastroenterology

Volumn 34, Issue 2, 1999, Pages 189-194

  Sakuma, Kazuhiro ^a   Fujimori, Takahiro ^a   Hirabayashi, Kaoru ^a   Terano, Akira ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; COX 2; Ki 67; p53

Indexed keywords

BIOTIN; CYCLOOXYGENASE 2; EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; STREPTAVIDIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STAINING; TUMOR DIFFERENTIATION; ULCERATIVE COLITIS;

ADULT; AGED; CELL NUCLEUS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; ISOENZYMES; KI-67 ANTIGEN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032909009     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350050242     Document Type: Article

References (23)

1. Dewitt DL, Day J, Sonnenburg WK, et al. Concentration of prostaglandin endoperoxide synthase and prostaglandin 12 synthase in the endothelium and smooth muscle of bovine aorta. J Clin Invest 1983;72:1882-8.
2. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
3. Waddel W, Ganser G, Cerise E, et al. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
4. Giovannuggi E, Egan K, Hunter D, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
5. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
6. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503.
7. Porschen R, Lohe B, Hengels KJ, et al. Assessment of cell proliferation in colorectal carcinomas using monoclonal antibody Ki-67. Correlation with pathohislologic criteria and influence of irradiation. Cancer 1989;64:2501-5.
8. Yukawa M, Fujimori T, Maeda S, et al. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumors. Gut 1994;35:1258-61.
9. DuBois RN, Shao J, Tsujii M, et al. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996;56:733-7.
10. Susan KB, Andrew JD, Amy C, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
11. Watson AJ, Dubois RN. Lipid metabolism and APC: implications for colorectal cancer prevention. Lancet 1997;349:444-5.
12. Fujimori T, Satonaka K, Yamamura-Idei Y, et al. Noninvolvement of ras mutations in flat colorectal adenomas and carcinomas. Int J Cancer 1994;57:51-5.
13. Yamamura-Idei Y, Satonaka K, Fujimori T, et al. p53 mutations in flat- and polypoid-type colorectal tumors detected by temperature-gradient gel electrophoresis. Dig Dis Sci 1994; 39:2043-8.
14. Yukawa M, Fujimori T, Maeda S, et al. Comparative clinicopathological and immunohistochemical study of ras and p53 in flat and polypoid type colorectal tumours. Gut 1994;35:1258-61.
15. Miyazaki J, Nagasako K, Asaka K, et al. Genetic changes of colorectal cancer in ulcerative colitis. J Jpn Soci Gastroenterol Carcinogenesis 1995;7:415-6.
16. Barnes CJ, Hardman WE, Cameron IL, et al. Aspirin, but not sodium salicilate, indomethacin, or nabumetone, reversibly suppress 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats. Dig Dis Sci 1997;42:920-6.
17. Yoshimi N, Kawabata K, Hara A, et al. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997;88:1044-51.
18. Pretlow TP. Aberrant crypt foci and K-ras mutations; earliest recognized players or innocent bystanders in colon carcinogenesis? Gastroenterology 1995;108:600-9.
19. Jen J, Powell SM, Papadopoulos N, et al. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;54:5523-6.
20. Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995;108: 434-40.
21. Tudek B, Bird RP, Bruce WR. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res 1989;49:1236-40.
22. McLellan EA, Medline A, Bird RP. Sequential analysis of the growth and morphological characteristics of aberrant crypt foci: Putative preneoplastic lesions. Cancer Res 1991;51: 5270-4.
23. Douglas JE Elder, Christos P: COX-2 inhibitors for colorectal cancer. Nature Medicine 1998;4:392-3.